Publicis

DEAR HEALTH (CONT’D)

20/09/22 -"Over the last three years, AlphaValue has been on a mission to call Health stocks expensive. That segment excludes Pharmas. The sector is down 30%, of which 7% over the last week. That still leaves ..."

PDF page sample
Pages
54
Language
English
Published on
20/09/22
Download
You may also be interested by these reports :
14/11/25
Wolters Kluwer announced a relatively small acquisition to reinforce its GenAI capabilities in legal. We think this is a smart acquisition as the ...
12/11/25
Informa delivered a good 10-month trading update, reaffirming its guidance for FY25 ahead of its CMD next week. The interesting news from this press ...
10/11/25
The revision of the target price reflects updates to EPS forecasts, as well as NAV and DCF adjustments. WPP faces a challenging situation, with ...
10/11/25
Our target price goes down substantially on the back of a (small) earnings revision, but mostly because of a change in our valuation metrics for both ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO